Aronora
OR - PortlandBiotechnology
Focus: Aronora is a publicly-traded biotechnology company focused on recombinant monoclonal antibodies and enzymes for cardiovascular and nephrology indications. The company operates as a clinical-stage biotech with a lean pipeline in early-to-mid development phases.
Profile data last refreshed 21h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Aronora
AI assessmentNot HiringNo open roles listed right now. Follow Aronora to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
xisomab 3G3
End Stage Renal DiseaseClinical Trials (2)
NCT03612856Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis
Phase 2Help build intelligence for Aronora
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.